✕
Login
Register
EN
Translate page
EN
English
ES
Español
FR
Français
DE
Deutsch
ZH
中文
AR
العربية
PT
Português
RU
Русский
JA
日本語
KO
한국어
HI
हिन्दी
IT
Italiano
Back to News
Ionis Pharmaceuticals Announces License Agreement With Recordati For Zilganersen In Alexander Disease In All Countries Outside The US For $30M Upfront Payment
Benzinga Newsdesk
www.benzinga.com
Positive 72.9%
Neg 0%
Neu 0%
Pos 72.9%
- Recordati brings deep rare disease expertise and proven capabilities in commercialization, access and country-specific regulatory environments -
- Ionis to independently commercialize zilganersen in the U.S. assuming FDA approval -
Comments
No comments yet. Be the first!
Join the discussion
Login to comment
Login to comment